Beijing QL Biopharmaceutical announced that its once-monthly GLP-1 receptor agonist, zovaglutide, achieved primary and secondary endpoints in a phase II obesity trial, demonstrating weight loss efficacy competitive with current weekly therapies and progressing to phase III. Additional metabolic advances include Eli Lilly filing for approval of Mounjaro for pediatric diabetes following successful phase III trials. Research also explores genetic tests to predict individual pharmacologic responses in obesity treatment, signaling a future toward precision medicine in metabolic diseases.